Eledon Pharmaceuticals, INC 10-Q quarterly reports

Eledon Pharmaceuticals reported a wider net loss for Q1 2026, driven by increased manufacturing costs and R&D expenses, while cash reserves remain substantial.

Eledon Pharmaceuticals reports a significant net loss in Q3 2025, alongside mixed Phase 2 kidney transplant trial results and substantial capital raises to fund ongoing operations.

Eledon Pharmaceuticals reported a significantly reduced net loss for Q2 2025, driven by a decrease in warrant liabilities and strategic focus on kidney transplantation programs, while noting the need for additional financing for its ALS program.

Eledon Pharmaceuticals, Inc. filed an amended quarterly report to restate prior financial statements due to accounting errors, while reporting reduced net losses and progress in clinical trials for its lead drug candidate, tegoprubart.

Eledon Pharmaceuticals announces its Q1 2025 financial results, focusing on the advancement of its kidney transplantation program and ongoing clinical trials.

Eledon Pharmaceuticals reported a net income of $77 million for the third quarter of 2024, primarily driven by a gain in the fair value of warrant liabilities, while also detailing ongoing clinical trials and financial activities.

Eledon Pharmaceuticals' Q2 2024 report highlights clinical trial advancements, a recent private placement, and a restatement of prior financial statements due to warrant accounting.

Eledon Pharmaceuticals has restated its first quarter 2024 financials due to an accounting error related to the classification of certain warrants, leading to a material weakness in internal controls.

Eledon Pharmaceuticals announced its first quarter 2024 financial results, highlighting a net loss of $10.3 million and securing $50 million in a private placement to extend its cash runway through December 2025.